Notizie AIOM – anno XVII
NCCN Goes Global With Guidelines Tailored for Treatment Capabilities Abroad
May 20, 2019 - Limited financial and medical resources available to cancer treatment centers in developing nations often make it difficult for physicians there to follow best practices widely adopted in the United States and other highly affluent countries. The National ...Leggi tutto
ASTRO and AUA Announce Updates to Joint Clinical Guidance for Adjuvant and Salvage Radiotherapy After Prostatectomy
May 20, 2019 - The American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA) recently announced updates to their joint clinical guideline on adjuvant and salvage radiotherapy after prostatectomy in patients with and without evidence of ...Leggi tutto
American Cancer Society Sets 2035 Cancer Mortality Reduction Goal
May 20, 2019 - The American Cancer Society (ACS) has set a challenge goal to reduce overall cancer mortality 40% between 2015 and 2035 - a goal set by applying favorable cancer mortality trends among college graduates to the population as a whole. A report on the goal was ...Leggi tutto
Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial
Nintedanib targets VEGF receptors 1–3, PDGF receptors α and β, FGF receptors 1–3, and Src and Abl kinases, which are all implicated in malignant pleural mesothelioma pathogenesis. Here, we report the final results of the phase 3 part of the LUME-Meso ...Leggi tutto
Restrictions in use of tofacitinib while EMA reviews risk of blood clots in lungs
May 17, 2019 - EMA’s safety committee (PRAC) is recommending that doctors must not prescribe the 10 mg twice daily dose of tofacitinib in patients who are at high risk of blood clots in the lungs. These include patients who have heart failure, cancer, inherited blood ...Leggi tutto
Withdrawal of marketing authorisations for fenspiride medicines
May 17, 2019 - EMA’s safety committee (PRAC) has recommended that the marketing authorisations for fenspiride medicines be revoked, so the medicines can no longer be marketed in the EU. This follows a review that has confirmed that these cough medicines could cause ...Leggi tutto